Float 16 M shares BB14+FMR 2=16 m
BOD(6 members) all delivered small amounts of shares spending money for a few months as the stock lays dead in the water?
All readers may want to read the June 27, 2013 "letter to investors" on Genomic Healths site for answers about how they do their science.
Small companies like GHDX never get to make the big money,a bigger pharma/Co always comes in for the kill and the quick buck insiders and shareholders love. Would you take $65 tomorrow?,if not a majority would.
So true.The pieces of the company in R&D in laying out the international markets and science verification and a stock selling for 3 X revenues means the groundwork is being laid for a Baker Brothers sale.
Credit Suisse joined BAC and others all downgrading interestingly enough to "Neutral" No sells all in the mid 30s " and have attacked the stock. Volume taking down the stock 25% was very low meaning someone is buying the shares.Guess who.
Got out 20% ago. The call was 11% growth but guidance was on the lower side,but 20%? When promising bios are about to announce a merger a takeover they push the stock down as hard as possible.Bet you will soon see the Bakers newest SEC doc.accumulating.buying a lot.just hit below 36 wow!
Bakers have been here since low digits.I do not see how the company commands a healthy premium.Company going private being so small will leave shareholders with a min return
Sold out most of my position at years end after consulting with the company.They do not plan for a sales pickup from the prostate trial for another 6-9 months as various world agencies have not officially sanctioned the test. Company continues to be barely profitable with a crazy PE.There is serious competition from other countries
this trade brings trash from here elsewhere.It looks like you have a new slew of circus performers besides your "kevie".
good message but the timeline allows for a huge variance in price
another reason could be that the Bakers own the company and take it private.Many here are in for years at a much lower cost and the Bakers are in for pennies.Going private at a lower cost is a distinct possibility.
What is important to notice is that Insiders control 53% and going private is a possibility.The Bakers are M&A artists but maybe they'll make an exception in this case since the genomic market is expected to grow to 25 B